Table of Content

1. Report Overview
1.1 Global Overview of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2018
1.2 Benefits of This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methods of the Study
1.7 Frequently Asked Questions (FAQ)

2. Introduction to the Checkpoint Inhibitor Anti-Cancer Treatment Drugs World Market 2018
2.1 Checkpoint Inhibitors: A New Era in Immunotherapy
2.2 Checkpoint Inhibitor Treatment Drugs in Oncology
2.3 Application Segment
2.3.1 Lung Cancer
2.3.2 Bladder Cancer
2.3.3 Melanoma
2.3.4 Hodgkin Lymphoma

3. Leading Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market Forecasts 2019-2029 and Leading Companies in the World Market
3.1 Leading Checkpoint Inhibitor Anti-Cancer Treatment Drugs in the Market 2019
3.1.1 Yervoy (ipilimumab) – Bristol-Myers Squibb
3.1.1.1 Yervoy: Sales Analysis
3.1.2 Opdivo (nivolumab) – Bristol-Myers Squibb/Ono Pharmaceutical
3.1.2.1 Opdivo: Sales Analysis
3.1.3 Keytruda (pembrolizumab) – Merck & Co.
3.1.3.1 Keytruda: Sales Analysis
3.2 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market in 2018
3.2.1 Bristol-Myers Squibb Leads the Market

4. Checkpoint Inhibitor Anti-Cancer Treatment Drugs: World Market 2019-2029
4.1 The Global Market for Checkpoint Inhibitor Anti-Cancer Treatments in 2018
4.2 The World Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market: Revenue Forecasts 2019-20
4.3 Leading Checkpoint Inhibitor Anti-Cancer Treatment Drugs Submarkets Forecast 2019-2029
4.3.1 The CTLA-4 Inhibitors Submarket Forecast 2019-2029
4.3.2 The PD-1 Inhibitors Submarket Forecast 2019-2029
4.3.3 Changing Market Shares: PD-1 Inhibitors Will Lead the Market
4.3.4 Market Dynamics of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
4.3.4.1 Drivers of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
4.3.4.2 Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
4.3.4.3 Opportunity of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
4.3.4.4 Trends of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market

5. Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
5.1 Epidemiology of Major Cancer types
5.1.1 Lung Cancer
5.1.2 Bladder Cancer
5.1.3 Melanoma
5.1.4 Hodgkin Lymphoma
5.1.5 Pancreatic Cancer
5.2 Regional Breakdown of the World Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
5.3 World Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Regional Forecast, 2019-2029
5.3.1 How Will Regional Market Shares Change by 2029?
5.4 The US Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
5.5 The EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
5.5.1 Germany: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
5.5.2 France: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
5.5.3 Italy: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
5.5.4 The UK: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
5.5.5 Spain: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
5.6 Japan: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
5.7 The APAC Market: Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029

6. The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Pipeline Analysis 2019-2029
6.1 Anti-PD-1 Inhibitors and Anti-PD-L1 Inhibitors
6.1.1 Tecentriq (Atezolizumab)
6.1.2 Pidilizumab (CT-011) – CureTech, Ltd.
6.1.3 AMP-224 – GSK/Amplimmune
6.1.4 REGN2810 – Regeneron/Sanofi
6.1.5 Libtayo
6.2 CTLA-4 Inhibitors
6.2.1 Tremelimumab (CP-675,206) - AstraZeneca
6.3 LAG-3 (lymphocyte activation gene-3) Inhibitors
6.3.1 IMP321- Prima Biomed
6.3.2 BMS-986016 - Bristol-Myers Squibb
6.3.3 IMP701 – Prima BioMed/Novartis
6.4 KIR Inhibitors
6.4.1 Lirilumab (IPH2102/BMS-986015) – Innate Pharma/Bristol-Myers Squibb
6.5 Anti-NKG2A Inhibitors
6.5.1 IPH2201 – Innate Pharma/AstraZeneca/MedImmune
6.6 Other Checkpoint Inhibitors
6.6.1 VISTA Inhibitors
6.6.1.1 CA-170 – Curis Inc/Aurigene Discovery Technologies
6.6.1.2 NLG919 – NewLink Genetics
6.6.1.3 INCB024360 – Incyte/Roche
6.6.2 A2aR Inhibitors
6.6.2.1 HTL-1071 – AstraZeneca/Heptares
6.7 Clinical trial landscape for Immune checkpoint inhibitors
6.8 Clinical trial landscape for pd1/L1 Immune checkpoint inhibitors

7. Qualitative Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
7.1 SWOT Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
7.1.1 Strengths and Weaknesses of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
7.1.1.1 A Novel Treatment Method that Harnesses the Immune System’s Vast Potential
7.1.1.2 Pricing of the Treatments Will Attract Companies
7.1.1.3 Cost of Treatment Will Restrain Market Access
7.1.1.4 Side Effects May Prohibit Growth
7.1.2 Opportunities and Threats for the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
7.1.2.1 Biomarkers Pave the Way for Optimum Utility
7.1.2.2 Combination Therapies are Achieving Superior Results
7.1.2.3 The Cost Burden of Expensive Drug Treatments on Healthcare Systems
7.1.2.4 Crowding of the Market with Similar Products

8. Company Profiles
8.1 AstraZeneca Plc.
8.1.1 Company Overview
8.1.2 Key Developments
8.2 Bristol-Myers Squibb Co.
8.2.1 Company Overview
8.2.2 Key Developments
8.3 Celldex Therapeutics Inc.
8.3.1 Company Overview
8.3.2 Key Developments
8.4 Incyte Corporation
8.4.1 Company Overview
8.4.2 Key Developments
8.5 Merck & Co., Inc.
8.5.1 Company Overview
8.5.2 Key Developments
8.6 Novartis Ag
8.6.1 Company Overview
8.6.2 Key Developments
8.7 Pfizer Inc.
8.7.1 Company Overview
8.7.2 Key Developments
8.8 Roche Holding Ag
8.8.1 Company Overview
8.8.2 Key Developments

9. Conclusions
9.1 The Global Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Current World Outlook
9.1.1 Driver for Growth: A Robust and Innovative Pipeline for the Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market to 2029
9.2 Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2019-2029: The US and EU Will Retain Their Lead
9.3 The Future of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market

Appendices

List of Tables


Table 2.1 Main Types of Checkpoint Inhibitors in Development, 2018
Table 3.1 Yervoy (Ipilimumab): Historical Sales ($bn, AGR%), 2015-2018
Table 3.2 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 3.3 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 3.4 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2024
Table 3.5 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2025-2029
Table 3.6 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 3.7 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%),2024-2029
Table 3.8 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Revenue ($bn), Market Share (%), 2018
Table 4.1 Global Market for Checkpoint Inhibitor Anti-Cancer Treatment Drugs: Revenues ($bn) and Market Shares (%) by Class, 2018
Table 4.2 Checkpoint Inhibitors by Revenue ($bn), 2018
Table 4.3 Checkpoint Inhibitors by Revenue ($bn), 2018
Table 4.4 Global Market Forecast for Checkpoint Inhibitors Anti-Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2018-2024
Table 4.5 Global Market Forecast for Checkpoint Inhibitors Anti-Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2024-2029
Table 4.6 Global Market for Checkpoint Inhibitors Anti-Cancer Treatment Drugs: Revenues ($bn) and Market Shares (%) by Class, 2018
Table 4.7 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2018-2024
Table 4.8 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2024-2029
Table 4.9 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2018-2024
Table 4.10 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2024-2029
Table 4.11 Global Market Forecast for Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market by Class: Market Shares (%), 2018-2024
Table 4.12 Global Market Forecast for Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market by Class: Market Shares (%), 2024-2029
Table 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Sizes ($bn), Market Shares (%), 2018
Table 5.2 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2018-2024
Table 5.3 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2024-2029
Table 5.4 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares (%), 2018-2024
Table 5.5 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares (%), 2024-2029
Table 5.6 Forecast of the US Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 5.7 Forecast of the US Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 5.8 EU Market Shares (%), 2018-2024
Table 5.9 EU Market Shares (%), 2024-2029
Table 5.10 Forecast of the EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 5.11 Forecast of the EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 5.12 Forecast of the German Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 5.13 Forecast of the German Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 5.14 Forecast of the French Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 5.15 Forecast of the French Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 5.16 Forecast of the Italian Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 5.17 Forecast of the Italian Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 5.18 Forecast of the UK Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 5.19 Forecast of the UK Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 5.20 Forecast of the Spanish Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 5.21 Forecast of the Spanish Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 5.22 Forecast of the Japanese Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 5.23 Forecast of the Japanese Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 5.24 Forecast of the APAC Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 5.25 Forecast of the APAC Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 6.1 Selected Combination Therapies for Atezolizumab, 2018
Table 6.2 Tecentriq Forecast: Revenue ($bn), 2018-2024
Table 6.3 Tecentriq Forecast: Revenue ($bn), 2024-2029
Table 6.4 Libtayo Forecast: Revenue ($bn), 2018-2024
Table 6.5 Tremelimumab Forecast: Revenue ($bn), 2018-2024
Table 6.6 Tremelimumab Forecast: Revenue ($bn), 2024-2029
Table 7.1 Strengths and Weaknesses of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market, 2018
Table 7.2 Opportunities and Threats of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market, 2018
Table 8.1 AstraZeneca PLC. Profile 2018
Table 8.2: AstraZeneca: Key Developments
Table 8.3 Bristol-Myers Squibb Co. Profile 2018
Table 8.4: Bristol-Myers Squibb: Key Developments
Table 8.5 Celldex Therapeutics Inc. Profile 2018
Table 8.6: Celldex Therapeutics: Key Developments
Table 8.7 Incyte Corporation Profile 2018 (
Table 8.8: Incyte: Key Developments
Table 8.9 Merck & Co., Inc. Profile 2018
Table 8.10: Merck & Co.: Key Developments
Table 8.11 Novartis AG Profile 2018
Table 8.12: Novartis: Key Developments
Table 8.13 Pfizer Inc. Profile 2018 (
Table 8.14: Pfizer: Key Developments
Table 8.15: Roche Holding AG Profile 2018 (
Table 8.16: Roche: Key Developments
Table 9.1 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast by Region: Market Size ($bn), Market Share (%), CAGR (%), 2018, 2020, 2024, and 2029
Table 9.2 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecasts by Class: Market Size ($bn) Market Share (%), CAGR (%), 2018, 2020, 2024, and 2029

List of Figures


Figure 1.1 Global Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Segmentation Overview, 2019
Figure 3.1 Yervoy (ipilimumab): Historical Sales ($bn), 2015-2018
Figure 3.2 Yervoy Forecast, Revenue ($bn), 2018-2029
Figure 3.3 Opdivo Forecast, Revenue ($bn), 2018-2029
Figure 3.4 Keytruda Forecast, Revenue ($bn), 2018-2029
Figure 3.5 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market by Revenue: Market Shares, 2018 (%)
Figure 4.1 Global Market for Checkpoint Inhibitor Anti-Cancer Treatment Drugs: Market Shares by Class (%), 2018
Figure 4.2 Global Market Forecast for Checkpoint Inhibitors Anti-Cancer Treatment Drugs by Class: Market Sizes ($bn), 2018-2029
Figure 4.3 Global Market for Checkpoint Inhibitors Anti-Cancer Treatment Drugs: Market Shares by Class (%), 2018
Figure 4.4 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), 2018-2029
Figure 4.5 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), 2018-2029
Figure 4.6 Global Market for Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares by Class (%), 2024
Figure 4.7 Global Market for Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares by Class (%), 2029
Figure 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares (%), 2018
Figure 5.2 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Sizes ($bn), 2018-2029
Figure 5.3 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares (%), 2024
Figure 5.4 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares (%), 2029
Figure 5.5 Forecast of the US Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
Figure 5.6 Forecast of the EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
Figure 5.7 EU Market for the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market, by Leading Country (%), 2018
Figure 5.8 Forecast of the EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market, Market Sizes ($bn), 2018-2029
Figure 5.9 Forecast of the German Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
Figure 5.10 Forecast of the French Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
Figure 5.11 Forecast of the Italian Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
Figure 5.12 Forecast of the UK Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
Figure 5.13 Forecast of the Spanish Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
Figure 5.14 Forecast of the Japanese Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
Figure 5.15 Forecast of the APAC Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
Figure 6.1 Tecentriq Forecast: Revenue ($bn), 2018-2029
Figure 6.2 Tremelimumab Forecast: Revenue ($bn), 2018-2029
Figure 9.1 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast by Class: Market Sizes ($bn), 2018-2029
Figure 9.2 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecasts by Region: Market Size ($bn), 2018, 2020, 2024, and 2029